CSIMarket
 
Catalent Inc   (NYSE: CTLT)
 

Catalent Inc's Suppliers Performance

CTLT's Supply Chain




 
CTLT Costs vs Sales of Suppliers Growth Catalent Inc recorded an increase in cost of sales by 3.57 % year on year, relative to one quarter ago cost of sales fell by -8.18 % in Q1.

More on CTLT Suppliers



Catalent Inc recorded increase in cost of sales by 3.57 % year on year, compare to one quarter ago cost of sales fell by -8.18 % in Q1.

More on CTLT Suppliers




Catalent Inc's Comment on Supply Chain


The company utilizes raw materials and other inputs to manufacture products under supply agreements typically lasting two to seven years, with some agreements terminable on short notice. It maintains master service agreements for development solutions to facilitate customer access. As of June 30, 2024, the company's backlog, representing future service revenues, was $2.34 billion, down from $2.53 billion the previous year. This backlog includes firm orders and minimum volumes for manufacturing services, primarily in the Biologics and Pharma and Consumer Health segments. Approximately 78% of the backlog as of June 30, 2024, is expected to be recognized as revenue by the end of fiscal 2025. The company operates approximately 50 manufacturing facilities and development centers worldwide, totaling about 8 million square feet, with capabilities in regulatory, quality assurance, and in-house validation, all compliant with cGMP or other applicable requirements.

Catalent Inc's Comment on Supply Chain


The company utilizes raw materials and other inputs to manufacture products under supply agreements typically lasting two to seven years, with some agreements terminable on short notice. It maintains master service agreements for development solutions to facilitate customer access. As of June 30, 2024, the company's backlog, representing future service revenues, was $2.34 billion, down from $2.53 billion the previous year. This backlog includes firm orders and minimum volumes for manufacturing services, primarily in the Biologics and Pharma and Consumer Health segments. Approximately 78% of the backlog as of June 30, 2024, is expected to be recognized as revenue by the end of fiscal 2025. The company operates approximately 50 manufacturing facilities and development centers worldwide, totaling about 8 million square feet, with capabilities in regulatory, quality assurance, and in-house validation, all compliant with cGMP or other applicable requirements.







CTLT's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Catalent Inc 11,553.36 4,422.00 -413.00 16,900
SUBTOTAL 0.00 0.00 0.00 -


Sources: Catalent Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Catalent Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.